anti-amyloid-monoclonal

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

1. 47/100

   Updated Italian intersocietal recommendations for the appropriate use of anti-amyloid monoclonal antibodies in Alzheimer's disease

   ✓ Peer-reviewed alzhub usefulness score 47 out of 100. The journal of prevention of Alzheimer's disease · 2026-10-15 · Treatments

   With the European authorisation of lecanemab and donanemab, Italy is entering the era of disease-modifying therapy for early symptomatic Alzheimer's disease.

   • Treatments
   • Brain Scans
2. 83/100

   Incidence, severity, and associated risk factors for amyloid-related imaging abnormalities in anti-amyloid monoclonal antibody therapy for early Alzheimer's disease: a systematic review and meta-analysis

   ✓ Peer-reviewed alzhub usefulness score 83 out of 100. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026-10-02 · Treatments

   ARIA remains a significant safety concern in anti-amyloid mAb therapy, with incidence and severity influenced by genetic, neuroimaging, and treatment-related factors.

   • Treatments
   • Risk Factors
   • Side Effects
3. 50/100

   Prospective evaluation of systemic coagulation function during anti-amyloid monoclonal antibody therapy in Alzheimer's disease

   ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of thrombosis and thrombolysis · 2026-08-20 · Treatments

   Anti-amyloid monoclonal antibodies such as lecanemab are increasingly used to treat Alzheimer's disease (AD) and are associated with amyloid-related imaging abnormalities (ARIA), including hemorrhagic findings (ARIA-H).

   • Treatments
4. 88/100

   Comparative risk of amyloid-related imaging abnormalities with anti-amyloid-β monoclonal antibodies: A systematic review and penalized likelihood network meta-analysis of randomized trials

   ✓ Peer-reviewed alzhub usefulness score 88 out of 100. Journal of Alzheimer's disease : JAD · 2026-07-11 · Treatments

   BackgroundAnti-amyloid-β monoclonal antibodies represent a new class of disease-modifying therapies for Alzheimer's disease (AD).

   • Treatments
   • Clinical Trials
   • Side Effects
5. 84/100

   Pharmacological and Clinical Heterogeneity of Anti-Amyloid Monoclonal Antibodies in Early Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Trials

   ✓ Peer-reviewed alzhub usefulness score 84 out of 100. Medical sciences (Basel, Switzerland) · 2026-06-23 · Treatments

   Six randomized comparisons derived from four phase III trials involving 7695 participants met the eligibility criteria.

   • Treatments
   • Clinical Trials
6. 47/100

   Memory Consolidation and ARIA in Individuals Receiving Anti-amyloid Monoclonal Antibodies

   ✓ Peer-reviewed alzhub usefulness score 47 out of 100. The journal of prevention of Alzheimer's disease · 2026-02-27 · Treatments

   Amyloid related imaging abnormalities (ARIA) are the most significant risk associated with the use of anti-amyloid monoclonal antibodies (MAB) for Alzheimer's disease (AD).

   • Treatments
   • Side Effects
   • Genetics
7. 47/100

   Structural and Functional Determinants of ARIA-H Risk in Anti-Amyloid Monoclonal Antibodies: A Comparative Mechanistic Framework for Alzheimer's Immunotherapy Development

   ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Current neuropharmacology · 2026-01-01 · Treatments

   We identify a risk hierarchy for ARIA-H among anti-Aβ mAbs and link specific mAb biophysical properties-Aβ binding type, affinity for soluble oligomers, epitope specificity, Fc structure, and plaque clearance dynamics-directly to ARIA-H pathogenesis.

   • Treatments
   • Side Effects
   • Brain Biology
8. 45/100

   [Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer's Disease: Expert Recommendation for Standard MRI Protocol]

   ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of the Korean Society of Radiology · 2025-01-24 · Treatments

   The introduction of anti-amyloid therapies for Alzheimer's disease (AD), such as lecanemab (Lequembi ® ), which was recently approved in Korea, necessitates careful monitoring for amyloid-related imaging abnormalities (ARIA) using brain MRI.

   • Treatments
   • Brain Scans
   • Side Effects
9. 16/100

   N-terminal-targeted anti-amyloid monoclonal antibodies illuminate the therapy for Alzheimer’s disease: a systematic review and comprehensive meta-analysis

   ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv · 2023-11-22 · Treatments

   The administration of mAbs that specifically target the N-terminus of Aβ showed promising results in reducing Aβ burden and ameliorating cognitive decline.

   • Treatments
   • Brain Scans

All topic tags with their study counts